FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077384652> ?p ?o ?g. }

• W2077384652 endingPage "262" @default.
• W2077384652 startingPage "251" @default.
• W2077384652 abstract "Background: Hypogonadism and anemia are common comorbid conditions in dialysis patients. Testosterone replacement may improve such clinical parameters as anemia, sarcopenia, and low libido. Additionally, by increasing hemoglobin levels, testosterone replacement may allow for a dose reduction in recombinant human erythropoietin (rHuEPO), thereby reducing cost. Methods: This phase IV, single-center, placebo-controlled, double-blind study assessed the effect of transdermal testosterone on serum testosterone levels, rHuEPO dose required to maintain hemoglobin level, bone mineral content, lean body mass and fat content, cholesterol level, sexual function, and mood. Forty hypogonadal male hemodialysis patients who were administered rHuEPO were randomly assigned to 100 mg of topical 1% testosterone gel (Testim; Auxilium Pharmaceuticals, Norristown, PA) or placebo, applied daily for 6 months. Results: Forty men with a mean age of 56 years and baseline serum testosterone level less than 300 ng/dL (<10.4 nmol/L) participated in this trial. In men assigned to administration of transdermal testosterone, there was an increase beyond that in the placebo group in mean serum testosterone (77.1 ng/dL [2.7 nmol/L]), dihydrotestosterone (DHT; 0.8 nmol/L), and estradiol levels (6.3 pg/mL [23.0 pmol/L]) and a decrease in mean serum luteinizing hormone levels (−3.1 IU/L). Compared with subjects administered placebo, participants on testosterone replacement therapy did not show an appreciable change in rHuEPO dose (mean difference adjusted for baseline values, 12.6 U/kg/wk; P = 0.73), bone mineral density, lean body mass or fat content, cholesterol level, sexual function, or mood. Conclusion: Daily administration of 100 mg of topical 1% testosterone gel for 6 months failed to significantly increase serum testosterone or DHT levels in hypogonadal men with end-stage renal disease. Treatment with transdermal testosterone did not impact on rHuEPO requirement or clinical parameters in this small placebo-controlled study. Greater serum testosterone levels may be required to show clinical benefit in men with end-stage renal disease. Background: Hypogonadism and anemia are common comorbid conditions in dialysis patients. Testosterone replacement may improve such clinical parameters as anemia, sarcopenia, and low libido. Additionally, by increasing hemoglobin levels, testosterone replacement may allow for a dose reduction in recombinant human erythropoietin (rHuEPO), thereby reducing cost. Methods: This phase IV, single-center, placebo-controlled, double-blind study assessed the effect of transdermal testosterone on serum testosterone levels, rHuEPO dose required to maintain hemoglobin level, bone mineral content, lean body mass and fat content, cholesterol level, sexual function, and mood. Forty hypogonadal male hemodialysis patients who were administered rHuEPO were randomly assigned to 100 mg of topical 1% testosterone gel (Testim; Auxilium Pharmaceuticals, Norristown, PA) or placebo, applied daily for 6 months. Results: Forty men with a mean age of 56 years and baseline serum testosterone level less than 300 ng/dL (<10.4 nmol/L) participated in this trial. In men assigned to administration of transdermal testosterone, there was an increase beyond that in the placebo group in mean serum testosterone (77.1 ng/dL [2.7 nmol/L]), dihydrotestosterone (DHT; 0.8 nmol/L), and estradiol levels (6.3 pg/mL [23.0 pmol/L]) and a decrease in mean serum luteinizing hormone levels (−3.1 IU/L). Compared with subjects administered placebo, participants on testosterone replacement therapy did not show an appreciable change in rHuEPO dose (mean difference adjusted for baseline values, 12.6 U/kg/wk; P = 0.73), bone mineral density, lean body mass or fat content, cholesterol level, sexual function, or mood. Conclusion: Daily administration of 100 mg of topical 1% testosterone gel for 6 months failed to significantly increase serum testosterone or DHT levels in hypogonadal men with end-stage renal disease. Treatment with transdermal testosterone did not impact on rHuEPO requirement or clinical parameters in this small placebo-controlled study. Greater serum testosterone levels may be required to show clinical benefit in men with end-stage renal disease." @default.
• W2077384652 created "2016-06-24" @default.
• W2077384652 creator A5034016429 @default.
• W2077384652 creator A5050979003 @default.
• W2077384652 creator A5054537002 @default.
• W2077384652 creator A5068893430 @default.
• W2077384652 creator A5074187805 @default.
• W2077384652 creator A5082763966 @default.
• W2077384652 date "2006-02-01" @default.
• W2077384652 modified "2023-09-27" @default.
• W2077384652 title "Transdermal Androgen Therapy to Augment EPO in the Treatment of Anemia of Chronic Renal Disease" @default.
• W2077384652 cites W1593442063 @default.
• W2077384652 cites W1969247424 @default.
• W2077384652 cites W1970273450 @default.
• W2077384652 cites W1972532885 @default.
• W2077384652 cites W1974796251 @default.
• W2077384652 cites W1983279758 @default.
• W2077384652 cites W2001240037 @default.
• W2077384652 cites W2002568122 @default.
• W2077384652 cites W2042508422 @default.
• W2077384652 cites W2046807060 @default.
• W2077384652 cites W2049597076 @default.
• W2077384652 cites W2052809332 @default.
• W2077384652 cites W2075146216 @default.
• W2077384652 cites W2082249619 @default.
• W2077384652 cites W2091228725 @default.
• W2077384652 cites W2094888619 @default.
• W2077384652 cites W2103410619 @default.
• W2077384652 cites W2113264115 @default.
• W2077384652 cites W2132153521 @default.
• W2077384652 cites W2139876233 @default.
• W2077384652 cites W2146475970 @default.
• W2077384652 cites W2149217977 @default.
• W2077384652 cites W2155965183 @default.
• W2077384652 cites W2320357893 @default.
• W2077384652 cites W2338951617 @default.
• W2077384652 cites W2341004217 @default.
• W2077384652 cites W2412307587 @default.
• W2077384652 cites W2474157887 @default.
• W2077384652 cites W2907369646 @default.
• W2077384652 cites W4230202275 @default.
• W2077384652 cites W4232620432 @default.
• W2077384652 cites W4241078276 @default.
• W2077384652 doi "https://doi.org/10.1053/j.ajkd.2005.10.022" @default.
• W2077384652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16431254" @default.
• W2077384652 hasPublicationYear "2006" @default.
• W2077384652 type Work @default.
• W2077384652 sameAs 2077384652 @default.
• W2077384652 citedByCount "66" @default.
• W2077384652 countsByYear W20773846522012 @default.
• W2077384652 countsByYear W20773846522013 @default.
• W2077384652 countsByYear W20773846522014 @default.
• W2077384652 countsByYear W20773846522015 @default.
• W2077384652 countsByYear W20773846522016 @default.
• W2077384652 countsByYear W20773846522017 @default.
• W2077384652 countsByYear W20773846522018 @default.
• W2077384652 countsByYear W20773846522019 @default.
• W2077384652 countsByYear W20773846522020 @default.
• W2077384652 countsByYear W20773846522021 @default.
• W2077384652 countsByYear W20773846522022 @default.
• W2077384652 crossrefType "journal-article" @default.
• W2077384652 hasAuthorship W2077384652A5034016429 @default.
• W2077384652 hasAuthorship W2077384652A5050979003 @default.
• W2077384652 hasAuthorship W2077384652A5054537002 @default.
• W2077384652 hasAuthorship W2077384652A5068893430 @default.
• W2077384652 hasAuthorship W2077384652A5074187805 @default.
• W2077384652 hasAuthorship W2077384652A5082763966 @default.
• W2077384652 hasConcept C120863210 @default.
• W2077384652 hasConcept C126322002 @default.
• W2077384652 hasConcept C134018914 @default.
• W2077384652 hasConcept C142724271 @default.
• W2077384652 hasConcept C147583825 @default.
• W2077384652 hasConcept C204787440 @default.
• W2077384652 hasConcept C205679159 @default.
• W2077384652 hasConcept C27081682 @default.
• W2077384652 hasConcept C2775871022 @default.
• W2077384652 hasConcept C2778063415 @default.
• W2077384652 hasConcept C2778248108 @default.
• W2077384652 hasConcept C2778534260 @default.
• W2077384652 hasConcept C2779279991 @default.
• W2077384652 hasConcept C71924100 @default.
• W2077384652 hasConcept C98274493 @default.
• W2077384652 hasConceptScore W2077384652C120863210 @default.
• W2077384652 hasConceptScore W2077384652C126322002 @default.
• W2077384652 hasConceptScore W2077384652C134018914 @default.
• W2077384652 hasConceptScore W2077384652C142724271 @default.
• W2077384652 hasConceptScore W2077384652C147583825 @default.
• W2077384652 hasConceptScore W2077384652C204787440 @default.
• W2077384652 hasConceptScore W2077384652C205679159 @default.
• W2077384652 hasConceptScore W2077384652C27081682 @default.
• W2077384652 hasConceptScore W2077384652C2775871022 @default.
• W2077384652 hasConceptScore W2077384652C2778063415 @default.
• W2077384652 hasConceptScore W2077384652C2778248108 @default.
• W2077384652 hasConceptScore W2077384652C2778534260 @default.
• W2077384652 hasConceptScore W2077384652C2779279991 @default.
• W2077384652 hasConceptScore W2077384652C71924100 @default.
• W2077384652 hasConceptScore W2077384652C98274493 @default.
• W2077384652 hasIssue "2" @default.

• next